So Moderna has been in the media all over the place. It was Pfizer last week. Let's take a look at what has been said about Moderna.

Tonight news on a second vaccine Moderna announcing its vaccine is nearly 95% effective.

Drug giant Moderna announcing their vaccine trials showed that it is nearly 95% effective.

The nearly 95% effective.

The vaccine is 94.5% effective at stopping symptomatic infections.

We're looking at clear evidence that the vaccine can protect those at highest risk of severe disease.

Results come after similar results from Pfizer and add to growing confidence that vaccines can help end this pandemic.

So now we have two vaccines that are really quite effective. So I think this is a really strong step forward to where we want to be about getting control of this outbreak.

It is an extraordinary outcome frankly to have two different vaccines tested in different conditions by two different companies developed independently, yield very similar outcomes.

Our goal would be by the second quarter to have enough vaccine for every American that would like to get vaccinated.

If both companies get emergency operation, 20 million Americans could start getting the vaccines as soon as December.

Most experts tell me and I agree the best vaccine is the one you get. So don't wait for one vaccine over the other.

I mean just just right up front, listen to that doctor. Just don't wait. This is such a experimental product using technologies we've never used before.

Just the carefree carelessness of saying just doesn't even matter. Just eat him, eat him, eat him, oh go for it. Just go for it.

What could possibly go wrong? A total mutation of your DNA and the species as we know it.

But I remember we talked about this last week. I was looking at we were looking at Pfizer. I talked about how tiny the actual study group was.

Can you tell me what are the details of Moderna? Is this the more robust trial?

Well, I don't know. I don't think so personally, but so they announced it reached the trial reached its primary efficacy end point Moderna would be looking at the emergency use authorization filing with the FDA in quote coming weeks.

The analysis was based on 95 cases of which 90 cases of COVID-19 were observed in the placebo group versus five in the vaccinated group. So the case enrolled 30,000 people, but we're looking at you know that first in term analysis was 95 cases.

So the primary end point of this, which stopped this study, this part of the study for emergency use was mild symptoms and a PCR test as Peter Doshi said from the BMJ. So you're not looking at hospital administration hospital admissions ICU admissions deaf.

We're looking at just mild symptoms basically. I mean, it's in and so just to be perfectly clear because I'm hearing news agency saying this is going to end the pandemic.

Now are we when we look at this. I just want to make sure I've got this right. There is nothing in this study that says that this vaccine can stop transmission given the large asymptomatic group.

...